Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.29
TECH's Cash-to-Debt is ranked lower than
87% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. TECH: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
TECH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 21 Max: No Debt
Current: 0.29
0.29
No Debt
Equity-to-Asset 0.59
TECH's Equity-to-Asset is ranked lower than
51% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TECH: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
TECH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.88 Max: 0.98
Current: 0.59
0.51
0.98
Debt-to-Equity 0.51
TECH's Debt-to-Equity is ranked lower than
59% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. TECH: 0.51 )
Ranked among companies with meaningful Debt-to-Equity only.
TECH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.14 Max: 0.51
Current: 0.51
0.01
0.51
Debt-to-EBITDA 2.78
TECH's Debt-to-EBITDA is ranked lower than
51% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. TECH: 2.78 )
Ranked among companies with meaningful Debt-to-EBITDA only.
TECH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07  Med: 0.5 Max: 2.78
Current: 2.78
0.07
2.78
Interest Coverage 10.31
TECH's Interest Coverage is ranked lower than
84% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TECH: 10.31 )
Ranked among companies with meaningful Interest Coverage only.
TECH' s Interest Coverage Range Over the Past 10 Years
Min: 10.31  Med: No Debt Max: No Debt
Current: 10.31
10.31
No Debt
Piotroski F-Score: 7
Altman Z-Score: 6.22
Beneish M-Score: -2.55
WACC vs ROIC
11.43%
11.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 20.55
TECH's Operating Margin % is ranked higher than
88% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. TECH: 20.55 )
Ranked among companies with meaningful Operating Margin % only.
TECH' s Operating Margin % Range Over the Past 10 Years
Min: 20.55  Med: 47.84 Max: 58.1
Current: 20.55
20.55
58.1
Net Margin % 19.31
TECH's Net Margin % is ranked higher than
89% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. TECH: 19.31 )
Ranked among companies with meaningful Net Margin % only.
TECH' s Net Margin % Range Over the Past 10 Years
Min: 13.51  Med: 33.36 Max: 40.8
Current: 19.31
13.51
40.8
ROE % 12.26
TECH's ROE % is ranked higher than
88% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. TECH: 12.26 )
Ranked among companies with meaningful ROE % only.
TECH' s ROE % Range Over the Past 10 Years
Min: 8.31  Med: 15.21 Max: 22.91
Current: 12.26
8.31
22.91
ROA % 7.82
TECH's ROA % is ranked higher than
89% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TECH: 7.82 )
Ranked among companies with meaningful ROA % only.
TECH' s ROA % Range Over the Past 10 Years
Min: 5.66  Med: 14.28 Max: 22.16
Current: 7.82
5.66
22.16
ROC (Joel Greenblatt) % 51.80
TECH's ROC (Joel Greenblatt) % is ranked higher than
93% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. TECH: 51.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TECH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.8  Med: 99.2 Max: 113.75
Current: 51.8
51.8
113.75
3-Year Revenue Growth Rate 11.60
TECH's 3-Year Revenue Growth Rate is ranked higher than
72% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. TECH: 11.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TECH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 12.7 Max: 23
Current: 11.6
5.3
23
3-Year EBITDA Growth Rate 0.60
TECH's 3-Year EBITDA Growth Rate is ranked lower than
57% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. TECH: 0.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TECH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -0.7  Med: 17.5 Max: 82.9
Current: 0.6
-0.7
82.9
3-Year EPS without NRI Growth Rate 4.60
TECH's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. TECH: 4.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TECH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.2  Med: 19.2 Max: 58.7
Current: 4.6
-12.2
58.7
GuruFocus has detected 4 Warning Signs with Bio-Techne Corp TECH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TECH's 30-Y Financials

Financials (Next Earnings Date: 2019-02-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

TECH Guru Trades in Q3 2017

Joel Greenblatt 26,305 sh (New)
Leucadia National 2,827 sh (New)
Jim Simons 244,700 sh (+66.35%)
Ron Baron 1,520,228 sh (+1.35%)
George Soros Sold Out
Mairs and Power 1,444,480 sh (-0.31%)
Chuck Royce 659,009 sh (-9.77%)
Columbia Wanger 102,625 sh (-41.85%)
Ray Dalio 1,955 sh (-59.92%)
» More
Q4 2017

TECH Guru Trades in Q4 2017

Pioneer Investments 75,385 sh (New)
Columbia Wanger 264,889 sh (+158.11%)
Jim Simons 356,000 sh (+45.48%)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Ron Baron 1,516,975 sh (-0.21%)
Mairs and Power 1,434,557 sh (-0.69%)
Chuck Royce 622,726 sh (-5.51%)
Leucadia National 2,530 sh (-10.51%)
» More
Q1 2018

TECH Guru Trades in Q1 2018

Ray Dalio 8,567 sh (New)
Leucadia National 9,270 sh (+266.40%)
Pioneer Investments 82,421 sh (+9.33%)
Jim Simons 370,300 sh (+4.02%)
Ron Baron 1,520,323 sh (+0.22%)
Mairs and Power 1,378,347 sh (-3.92%)
Chuck Royce 570,355 sh (-8.41%)
» More
Q2 2018

TECH Guru Trades in Q2 2018

Jim Simons 413,800 sh (+11.75%)
Ron Baron 1,510,434 sh (-0.65%)
Mairs and Power 1,291,677 sh (-6.29%)
Pioneer Investments 76,658 sh (-6.99%)
Leucadia National 8,342 sh (-10.01%)
Ray Dalio 7,636 sh (-10.87%)
Chuck Royce 490,555 sh (-13.99%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OSTO:SOBI, NAS:IONS, HKSE:01530, HKSE:01548, BOM:532523, XKRX:215600, SZSE:000661, NAS:SRPT, NAS:EXEL, XKRX:128940, NAS:AGIO, TSE:4587, SZSE:300347, NAS:UTHR, XAMS:GLPG, NAS:SAGE, NAS:ALKS, SZSE:002007, XBRU:ABLX, SHSE:603233 » details
Traded in other countries:TE1.Germany,
Headquarter Location:USA
Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.

Bio-Techne is a biotechnology company that develops, manufactures, and sells biotechnology products for research and clinical diagnostic markets worldwide. Bio-Techne develops specialized proteins, including cytokines and growth factors, antibodies, related immunoassays, biologically-active small molecules, and other reagents, as well as instrumentation designed to simplify key protein analysis processes. The company also serves the clinical markets with regulated products such as controls, calibrators, reagents, and immunoassays intended for diagnostic uses.

Guru Investment Theses on Bio-Techne Corp

Royce Funds Comments on Bio-Techne - Jul 05, 2018

Bio-Techne (NASDAQ:TECH) was up about 16% through the end of May. It is one of the world’s largest producers of reagents (which are specialized proteins) used in drug research and development and clinical diagnostics. It’s a strong free cash flow business given the high incremental margin and annuity-like nature of the sales of these consumable products.



Equally important, the CEO has transformed the company in the five years since he came on board, taking a steady cash cow and turning it into a compounding growth machine by reinvesting in previously untapped opportunities such as faster and broader new product development, geographic expansion, salesforce growth, and acquisitions that supplemented its core business or enhanced its presence in the analytical instruments market.



The payoff from these actions has been evident in Bio-Techne’s robust financial results, and the market has rewarded the stock with valuation multiple expansion.



From Lauren Romeo on 4 Premier Quality Small-Caps.



Check out Chuck Royce latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 46.30
TECH's PE Ratio is ranked lower than
75% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. TECH: 46.30 )
Ranked among companies with meaningful PE Ratio only.
TECH' s PE Ratio Range Over the Past 10 Years
Min: 16.78  Med: 28.08 Max: 67.54
Current: 46.3
16.78
67.54
Forward PE Ratio 35.97
TECH's Forward PE Ratio is ranked lower than
62% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. TECH: 35.97 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 46.30
TECH's PE Ratio without NRI is ranked lower than
74% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. TECH: 46.30 )
Ranked among companies with meaningful PE Ratio without NRI only.
TECH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.78  Med: 28.08 Max: 67.54
Current: 46.3
16.78
67.54
Price-to-Owner-Earnings 48.64
TECH's Price-to-Owner-Earnings is ranked lower than
73% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. TECH: 48.64 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TECH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 17.03  Med: 26.99 Max: 64
Current: 48.64
17.03
64
PB Ratio 5.29
TECH's PB Ratio is ranked lower than
66% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TECH: 5.29 )
Ranked among companies with meaningful PB Ratio only.
TECH' s PB Ratio Range Over the Past 10 Years
Min: 3.27  Med: 4.48 Max: 6.95
Current: 5.29
3.27
6.95
PS Ratio 8.99
TECH's PS Ratio is ranked higher than
52% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TECH: 8.99 )
Ranked among companies with meaningful PS Ratio only.
TECH' s PS Ratio Range Over the Past 10 Years
Min: 6.63  Med: 8.66 Max: 12.48
Current: 8.99
6.63
12.48
Price-to-Free-Cash-Flow 40.99
TECH's Price-to-Free-Cash-Flow is ranked lower than
59% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. TECH: 40.99 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TECH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 17.68  Med: 27.38 Max: 53.91
Current: 40.99
17.68
53.91
Price-to-Operating-Cash-Flow 36.02
TECH's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. TECH: 36.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TECH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 15.74  Med: 24 Max: 47.41
Current: 36.02
15.74
47.41
EV-to-EBIT 46.79
TECH's EV-to-EBIT is ranked lower than
80% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. TECH: 46.79 )
Ranked among companies with meaningful EV-to-EBIT only.
TECH' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.4  Med: 18 Max: 62.2
Current: 46.79
10.4
62.2
EV-to-EBITDA 30.98
TECH's EV-to-EBITDA is ranked lower than
77% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. TECH: 30.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
TECH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.9  Med: 16.8 Max: 41.2
Current: 30.98
9.9
41.2
EV-to-Revenue 9.45
TECH's EV-to-Revenue is ranked higher than
55% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. TECH: 9.45 )
Ranked among companies with meaningful EV-to-Revenue only.
TECH' s EV-to-Revenue Range Over the Past 10 Years
Min: 6  Med: 8.3 Max: 12.6
Current: 9.45
6
12.6
PEG Ratio 31.87
TECH's PEG Ratio is ranked lower than
98% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. TECH: 31.87 )
Ranked among companies with meaningful PEG Ratio only.
TECH' s PEG Ratio Range Over the Past 10 Years
Min: 1.03  Med: 5.1 Max: 643.88
Current: 31.87
1.03
643.88
Shiller PE Ratio 49.78
TECH's Shiller PE Ratio is ranked lower than
66% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. TECH: 49.78 )
Ranked among companies with meaningful Shiller PE Ratio only.
TECH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 24.57  Med: 33.87 Max: 65.42
Current: 49.78
24.57
65.42
Current Ratio 4.59
TECH's Current Ratio is ranked higher than
59% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. TECH: 4.59 )
Ranked among companies with meaningful Current Ratio only.
TECH' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 7.65 Max: 21.99
Current: 4.59
2.15
21.99
Quick Ratio 3.50
TECH's Quick Ratio is ranked higher than
51% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. TECH: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
TECH' s Quick Ratio Range Over the Past 10 Years
Min: 1.7  Med: 6.74 Max: 21.04
Current: 3.5
1.7
21.04
Days Inventory 133.04
TECH's Days Inventory is ranked lower than
51% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. TECH: 133.04 )
Ranked among companies with meaningful Days Inventory only.
TECH' s Days Inventory Range Over the Past 10 Years
Min: 68.36  Med: 123.06 Max: 192.76
Current: 133.04
68.36
192.76
Days Sales Outstanding 63.33
TECH's Days Sales Outstanding is ranked lower than
53% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. TECH: 63.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
TECH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.81  Med: 50.66 Max: 75.74
Current: 63.33
40.81
75.74
Days Payable 30.37
TECH's Days Payable is ranked higher than
64% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. TECH: 30.37 )
Ranked among companies with meaningful Days Payable only.
TECH' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 32.89 Max: 46.43
Current: 30.37
28.64
46.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.82
TECH's Dividend Yield % is ranked lower than
70% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. TECH: 0.82 )
Ranked among companies with meaningful Dividend Yield % only.
TECH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.39  Med: 1.36 Max: 1.82
Current: 0.82
0.39
1.82
Dividend Payout Ratio 0.38
TECH's Dividend Payout Ratio is ranked lower than
69% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. TECH: 0.38 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TECH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.39 Max: 0.63
Current: 0.38
0.27
0.63
3-Year Dividend Growth Rate 0.30
TECH's 3-Year Dividend Growth Rate is ranked lower than
60% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. TECH: 0.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TECH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14
Current: 0.3
0
14
Forward Dividend Yield % 0.80
TECH's Forward Dividend Yield % is ranked lower than
72% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. TECH: 0.80 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.88
TECH's 5-Year Yield-on-Cost % is ranked lower than
71% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. TECH: 0.88 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TECH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.42  Med: 1.47 Max: 1.96
Current: 0.88
0.42
1.96
3-Year Average Share Buyback Ratio -0.40
TECH's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. TECH: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TECH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.6  Med: -0.3 Max: 2.4
Current: -0.4
-5.6
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.34
TECH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. TECH: 2.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TECH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.26  Med: 2.06 Max: 12.77
Current: 2.34
1.26
12.77
Price-to-Intrinsic-Value-DCF (Earnings Based) 4.33
TECH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
89% of the 38 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. TECH: 4.33 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
TECH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.69  Med: 1.11 Max: 5.78
Current: 4.33
0.69
5.78
Price-to-Median-PS-Value 1.04
TECH's Price-to-Median-PS-Value is ranked lower than
67% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. TECH: 1.04 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TECH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.97 Max: 3.02
Current: 1.04
0.13
3.02
Earnings Yield (Greenblatt) % 2.14
TECH's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. TECH: 2.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TECH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 5.6 Max: 9.6
Current: 2.14
1.6
9.6
Forward Rate of Return (Yacktman) % 2.37
TECH's Forward Rate of Return (Yacktman) % is ranked lower than
68% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. TECH: 2.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TECH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.9  Med: 8.8 Max: 20.8
Current: 2.37
1.9
20.8

More Statistics

Revenue (TTM) (Mil) $661.35
EPS (TTM) $ 3.35
Beta1.47
Volatility31.17%
52-Week Range $125.27 - 206.04
Shares Outstanding (Mil)37.77

Analyst Estimate

Jun19 Jun20 Jun21
Revenue (Mil $) 713 788 864
EBIT (Mil $) 156 198
EBITDA (Mil $) 235 279
EPS ($) 2.90 3.71 5.76
EPS without NRI ($) 2.90 3.71 5.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.06%
Dividends per Share ($) 1.28 1.29 1.28

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}